600664.SH
哈药股份
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 8.22
+0.61%Aug 25, 2026, 08:59 UTC
Harbin Pharmaceutical Group announced its first-half 2026 results: net profit attributable to shareholders of 410 million yuan, up 57.99% year-on-year.
Source:Aug 3, 2026, 09:41 UTC
Harbin Pharmaceutical announced that its subsidiaries Harbin General Factory and Harbin No.6 Factory have two products provisionally selected in the 12th national centralized drug procurement, with the procurement period lasting until December 31, 2029.
Source:Aug 2, 2026, 05:48 UTC
In July 2026, oil and gas extraction and innovative drug concept stocks rose against the market, with Harbin Pharmaceutical up 96.99% and Longshengongfa up 93.93% in the innovative drug sector, and Keli Co. up 56.82% and Tongyuan Petroleum up 49.13% in the oil and gas extraction sector.
Source:Jul 29, 2026, 07:33 UTC
Harbin Pharmaceutical's subsidiary Harbin Bio received an approval notice from China's National Medical Products Administration for the marketing application of potassium sulfate active pharmaceutical ingredient.
Source:Jul 13, 2026, 10:17 UTC
China's National Health Commission and other departments released the 2026 edition of the National Essential Medicines List, effective September 1, 2026, which includes 118 specifications from Harbin Pharmaceutical Group and its subsidiaries, with 6 new varieties added and 1 variety removed.
Source: